News

Filter

Current filters:

VivusMarkets & Marketing

1 to 9 of 11 results

Market for obesity therapies to reach a value of $2.6 billion in 2019

16-09-2013

The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report

05-09-2013

The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Vivus partners with Menarini for European and Australia/NZ marketing of ED drug

09-07-2013

US drugmaker Vivus (Nasdaq: VVUS) has entered into a license and commercialization agreement and a supply…

Asia-PacificavanafilEuropeLicensingMarkets & MarketingMen's HealthMenariniPharmaceuticalReproductiveSpedraVivus

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus announces new discount program for obesity drug Qsymia

06-03-2013

US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

Express Scripts adds Vivus' Qsymia to its standard benefits program

20-12-2012

US drugmaker Vivus (Nasdaq: VVUS) says that Express Scripts, among the USA's largest Pharmacy Benefit…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Strong start for Vivus' obesity drug Qsymia; deal with Express Scripts

10-10-2012

Sales of US drugmaker Vivus' (Nasdaq: VVUS) obesity agent Qsymia (phentermine and topiramate extended-release)…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus debuts weight-loss pill Qsymia on US market

19-09-2012

USA-based Vivus (Nasdaq: VVUS) saw its shares rise 3.9% to $22.93 on Monday, after the company announced…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

1 to 9 of 11 results

Back to top